[go: up one dir, main page]

ME00804B - Anti-alpha v beta 6 antitela - Google Patents

Anti-alpha v beta 6 antitela

Info

Publication number
ME00804B
ME00804B MEP-2009-200A MEP20009A ME00804B ME 00804 B ME00804 B ME 00804B ME P20009 A MEP20009 A ME P20009A ME 00804 B ME00804 B ME 00804B
Authority
ME
Montenegro
Prior art keywords
antibody
seq
αvβ6
light chain
sequence
Prior art date
Application number
MEP-2009-200A
Other languages
English (en)
French (fr)
Inventor
Michael Graupe
Paul Weinreb
Kenneth Simon
Dean Sheppard
Diane Leone
Original Assignee
Biogen Idec Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29586753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00804(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Univ California filed Critical Biogen Idec Inc
Publication of ME00804B publication Critical patent/ME00804B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Monoklonska antitela koja se specifično vezuju za  α v β 6 .  Uključeni su i postupci  korišćenja ovih antitela za tretiranje sisara koji imaju oboljenja u kojima posreduje  α v β 6 , ili su  pod rizikom da ih imaju, ili za dijagnostikovanje oboljenja u kojima posreduje  α v β 6 .

Claims (59)

1. Monoklonsko antitelo koje (a) se specifično vezuje za αvβ6 (b) inhibira vezivanje αvβ6 za peptid vezan za latenciju (LAP) sa vrednošću IC50 nižom od one 10D5.
2. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.1A8 (ATCC pristupni broj PTA-3647).
3. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.309 (ATCC pristupni broj PTA-3649).
4. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.806 (ATCC pristupni broj PTA-3645).
5. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2B l (ATCC pristupni broj PTA-3646).
6. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 7.l G l O (ATCC pristupni broj PTA-3898).
7. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 7.705 (ATCC pristupni broj PTA-3899).
8. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 7.1CS (ATCC pristupni broj PTA-3900).
9. Antitelo prema zahtevu l, gde je vezivanje između antitela i αvβ6 zavisno od dvovalentnih katjona.
10. Antitelo prema zahtevu l , gde je dvovalentni katjon Ca2+, Mg2+ ili Mn2+
11. Antitelo prema zahtevu l , gde je vezivanje između antitela i αvβ6 nezavisno od dvovalentnih katjona.
12. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: l , 4 i 7, respektivno, i čiji se CDR ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: l O, 13 i 15, respektivno.
13. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 3, 5 i 8, respektivno, i čiji se CDR ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 11, 14 i 17, respektivno.
14. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 3, 6 i 9, respektivno, i čiji se CDR ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 12, 14 i 18, respektivno.
15. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 2, 46 i 47, respektivno, i čiji se CDR-ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 48, 13 i 16, respektivno.
16. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 49, 51, i 53, respektivno, i čiji se CDR-ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 55, 57 i 59, respektivno.
17. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 50, 52, i 54, respektivno, i čiji se CDR-ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 56, 58 i 60, respektivno.
18. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži bilo koju od SEQ ID NOs: 19-36 i 61-62.
19. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 19, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 37.
20. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID N0:20 ili 21 , a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 38.
21. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID N0:22, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 43.
22. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 23, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 44.
23. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 24, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 45.
24. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 25 ili 26, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 42.
25. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 27, 28, ili 29, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 39.
26. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 34 ili 35, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 40.
27. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 36, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 41.
28. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 61, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 63.
29. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 62, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 64.
30. Monoklonsko antitelo koje se specifično vezuje za αvβ6, ali ne inhibira vezivanje αvβ6 za peptid vezan za latenciju (LAP).
31. Antitelo prema zahtevu 30, gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2A l (ATCC pristupni broj PTA-3896).
32. Antitelo prema zahtevu 30, gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2E5 (ATCC pristupni broj PTA-3897).
33. Kompozicija za sprečavanje ili lečenje oboljenja u kojem posreduje αvβ6 kod sisara, koja sadrži antitelo iz bilo kog od zahteva 1-32, i farmaceutski prihvatljiv nosač.
34. Kompozicija prema zahtevu 33, gde je antitelo konjugovano sa citotoksičkim agensom.
35. Kompozicija prema zahtevu 33, gde je antitelo zavisno od katjona.
36. Postupak za tretiranje subjekta koji ima ili je pod rizikom da ima oboljenje u kojem posreduje αvβ6, koji se sastoji od davanja subjektu kompozicije iz zahteva 32, čime se ublažava oboljenje ili odlaže njegov početak.
37. Postupak prema zahtevu 36, gde je subjekt čovek.
38. Postupak prema zahtevu 36, gde je oboljenje fibroza.
39. Postupak prema zahtevu 38, gde je fibroza skleroderma, stvaranje ožiljaka, fibroza jetre, fibroza bubrega ili fibroza pluća.
40. Postupak prema zahtevu 36, gde je oboljenje psorijaza.
41. Postupak prema zahtevu 36, gde je oboljenje kancer.
42. Postupak prema zahtevu 41, gde je kancer epitelni kancer.
43. Postupak prema zahtevu 41, gde je kancer oralan, kancer kože, cerviksa, jajnika, farinksa, larinksa, ezofagusa, pluća, dojke, bubrega ili kolorektalni kancer.
44. Postupak prema zahtevu 36, gde je oboljenje Alport-ov sindrom.
45. Postupak detektovanja αvβ6 u uzorku tkiva sisara, koji se sastoji od dovođenja u kontakt uzorka tkiva sa antitelom iz zahteva l ili 30.
46. Postupak prema zahtevu 45, gde je antitelo odabrano iz grupe koju čine 6.2Al (ATCC pristupni broj PTA 3896) i 6.2E5 (ATCC pristupni broj PTA 3897).
47. Ćelija hibridoma 6.1A8 (ATCC pristupni broj PTA-3647).
48. Ćelija hibridoma 6.2B10 (ATCC pristupni broj PTA-3648).
49. Ćelija hibridoma 6.3G9 (ATCC pristupni broj PTA-3649).
50. Ćelija hibridoma 6.8G6 (ATCC pristupni broj PTA-3645).
51. Ćelija hibridoma 6.2Bl (ATCC pristupni broj PTA-3646).
52. Ćelija hibridoma 6.2Al (ATCC pristupni broj PTA-3896).
53. Ćelija hibridoma 6.2E5 (ATCC pristupni broj PTA-3897).
54. Ćelija hibridoma 7.1G lO (ATCC pristupni broj PTA-3898).
55. Ćelija hibridoma 7.7G5 (ATCC pristupni broj PTA-3899).
56. Ćelija hibridoma 7.1C5 (ATCC pristupni broj PTA-3900).
57. Izolovana nukleinska kiselina koja sadrži kodirajuću sekvencu za bilo koju od SEQ ID NOs: 19-45 i 61-64.
58. Izolovan polipeptid koji sadrži bilo koju aminokiselinsku sekvencu od SEQ ID NOs: 19-45 i 61-64.
59. Monoklonsko antitelo koje se sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2B 10 (ATCC pristupni broj PTA-3648).
MEP-2009-200A 2002-03-13 2003-03-13 Anti-alpha v beta 6 antitela ME00804B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36499102P 2002-03-13 2002-03-13
US42628602P 2002-11-13 2002-11-13
PCT/US2003/008048 WO2003100033A2 (en) 2002-03-13 2003-03-13 ANTI-αvβ6 ANTIBODIES

Publications (1)

Publication Number Publication Date
ME00804B true ME00804B (me) 2012-03-20

Family

ID=29586753

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-200A ME00804B (me) 2002-03-13 2003-03-13 Anti-alpha v beta 6 antitela

Country Status (23)

Country Link
US (4) US7465449B2 (me)
EP (4) EP1490110B1 (me)
JP (6) JP4473117B2 (me)
KR (1) KR101098109B1 (me)
CN (4) CN102924598B (me)
AR (1) AR038970A1 (me)
AU (1) AU2003261071C1 (me)
BR (1) BRPI0308585B8 (me)
CA (1) CA2478833C (me)
CL (8) CL2010000790A1 (me)
EA (1) EA011853B1 (me)
ES (1) ES2389037T3 (me)
HK (1) HK1213007A1 (me)
IL (4) IL164021A0 (me)
IS (1) IS7443A (me)
ME (1) ME00804B (me)
MX (1) MXPA04008870A (me)
MY (2) MY147019A (me)
NO (1) NO334834B1 (me)
NZ (2) NZ535425A (me)
PL (1) PL216223B1 (me)
RS (1) RS52488B (me)
WO (1) WO2003100033A2 (me)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
AU2012258386B2 (en) * 2005-07-08 2014-08-07 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
EP1974213A4 (en) * 2006-01-17 2009-03-25 Biosite Inc HIGHLY SENSITIVE SECRETAGOGIN ASSAYS AND ITS USE IN DIAGNOSIS AND / OR FORECASTING
SG173364A1 (en) * 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
JP5362563B2 (ja) * 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
EP2087008A1 (en) * 2006-10-19 2009-08-12 The Regents of the University of California TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
DK2164992T3 (en) * 2007-05-30 2016-08-15 Lpath Inc COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
KR101581733B1 (ko) * 2007-11-16 2015-12-31 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
JP5766598B2 (ja) 2008-05-07 2015-08-19 アーゴス セラピューティクス インコーポレイテッド ヒトインターフェロン−αに対するヒト化抗体
CA2723842A1 (en) * 2008-05-09 2009-11-12 Peter Vanlandschoot Amino acid sequences directed against integrins and uses thereof
CN102099491A (zh) * 2008-05-15 2011-06-15 北卡罗来纳-查佩尔山大学 调节血管生成的新靶标
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
SG178348A1 (en) 2009-08-19 2012-03-29 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
WO2011119524A1 (en) * 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
EP2824111B1 (en) 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
AU2013221585B2 (en) * 2012-02-17 2017-03-30 Seagen Inc. Antibodies to integrin alphavbeta6 and use of same to treat cancer
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
CA2886772C (en) * 2012-10-03 2021-01-12 Livtech, Inc. Anti-hdlk-1 antibody having an anti-tumor activity in vivo
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014144466A1 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
ES2883191T3 (es) 2013-08-30 2021-12-07 Immunogen Inc Anticuerpos y ensayos para la detección del receptor 1 de folato
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
EP3052523B1 (en) * 2013-10-01 2021-03-10 Medimmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
EP3052522B1 (en) 2013-10-03 2019-12-11 Biocare Medical, LLC Anti-sox10 antibody systems and methods
CN104721225A (zh) 2013-12-19 2015-06-24 高露洁-棕榄公司 口腔护理组合物
PE20160996A1 (es) 2013-12-23 2016-11-09 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
PE20180610A1 (es) 2015-06-22 2018-04-09 Bayer Pharma AG CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
CN108135986B (zh) * 2015-08-13 2022-07-29 纽约大学 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
HK1255141A1 (zh) 2015-09-17 2019-08-09 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017162663A1 (de) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2018017797A1 (en) * 2016-07-22 2018-01-25 Georgia State Universtiy Research Foundation Monoclonal antibodies to b virus and their use for identification of b virus specific reactive peptides
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
KR102486434B1 (ko) 2016-11-08 2023-01-09 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4233902A3 (en) 2016-12-14 2024-02-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
IL310558B1 (en) 2016-12-21 2025-10-01 Bayer Pharma AG Antibody-drug conjugates with enzymatically cleavable groups
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
GB201720989D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IL278642B2 (en) 2018-05-11 2023-10-01 Glaxosmithkline Ip Dev Ltd Furin inhibitors
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CA3136488A1 (en) * 2019-04-08 2020-10-15 Biogen Ma Inc. Anti-integrin antibodies and uses thereof
GB201908536D0 (en) 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
EP4065167A4 (en) * 2019-11-26 2024-03-27 Children's Hospital Medical Center CELA-1 INHIBITION FOR THE TREATMENT OF LUNG DISEASE
US11827709B2 (en) 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
JP2024505001A (ja) * 2021-01-26 2024-02-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ａｖｂ８インテグリンに関連する疾患を処置および予防するための組成物および方法
CA3205921A1 (en) 2021-02-03 2022-08-11 Sheng CUI Formulation of furin inhibitor for inhalation
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
WO2024263932A2 (en) 2023-06-23 2024-12-26 Mythic Therapeutics, Inc. Itgb6-binding proteins and uses thereof
WO2025064435A1 (en) 2023-09-19 2025-03-27 Imaginab, Inc. Antigen binding constructs directed to integrin αvβ6
WO2025163120A1 (en) 2024-02-01 2025-08-07 Adcytherix Sas ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69230142T2 (de) * 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6417324B1 (en) * 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
DK0719859T3 (da) * 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
HUP9901673A3 (en) 1995-08-17 2001-06-28 Scil Biomedicals Gmbh Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU718138B2 (en) 1995-08-29 2000-04-06 Kyowa Hakko Kirin Co., Ltd. Chimeric animal and method for constructing the same
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
WO1997046589A2 (en) * 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
AU6721696A (en) 1996-07-15 1998-03-06 Human Genome Sciences, Inc. Cd44-like protein
US5789422A (en) 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5783579A (en) 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
PT996460E (pt) * 1997-08-08 2005-04-29 Univ California Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6
PL341569A1 (en) 1998-01-23 2001-04-23 Merck Patent Gmbh Monoclonal anti-alphav-integrin antibody and application thereof as an inhibitore of alphavbeta6-integrin to fibronectin bond
JP2002533064A (ja) 1998-12-19 2002-10-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング インテグリンαｖβ６阻害剤
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
EE200300509A (et) 2001-04-13 2004-08-16 Biogen, Inc. Antikehad VLA-1 vastu
DE10118550A1 (de) 2001-04-14 2002-10-17 Merck Patent Gmbh Liganden des Integrins alpha¶nu¶beta¶6¶
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
EP3674322A1 (en) 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
NZ535425A (en) * 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
US20040048312A1 (en) 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
AU2003298783B2 (en) 2002-11-26 2010-11-04 Abbvie Biotherapeutics Inc. Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US20070117849A1 (en) 2003-10-01 2007-05-24 Simon Goodman Alfavbeta3 and alfavbet6 integrin antagonists as antifibrotic agents
ES2343840T3 (es) 2003-11-04 2010-08-11 Bayer Healthcare Llc Procedimientos inmunohistoquimicos para supervisar los niveles de perk.
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2087008A1 (en) 2006-10-19 2009-08-12 The Regents of the University of California TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6
GB0803192D0 (en) 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
US20120004129A1 (en) 2008-12-23 2012-01-05 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
HK1208470A1 (en) 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
NZ563951A (en) 2009-04-30
BR0308585A (pt) 2005-02-01
US20120251532A1 (en) 2012-10-04
CN104805090A (zh) 2015-07-29
JP2015126743A (ja) 2015-07-09
CL2010000785A1 (es) 2011-02-18
CL2010000786A1 (es) 2011-02-18
CL2010000789A1 (es) 2011-02-18
EP2287198A2 (en) 2011-02-23
EA011853B1 (ru) 2009-06-30
IL164021A0 (en) 2005-12-18
CL2010000787A1 (es) 2011-02-11
US8153126B2 (en) 2012-04-10
NZ535425A (en) 2008-05-30
US9745376B2 (en) 2017-08-29
WO2003100033A2 (en) 2003-12-04
IL164021A (en) 2013-04-30
EP2287198A3 (en) 2011-05-25
JP4473117B2 (ja) 2010-06-02
BRPI0308585B1 (pt) 2019-10-15
EA200401198A1 (ru) 2005-04-28
EP2336185A1 (en) 2011-06-22
KR101098109B1 (ko) 2011-12-26
CA2478833C (en) 2015-11-10
MY154009A (en) 2015-04-30
US7465449B2 (en) 2008-12-16
EP2287199B1 (en) 2017-08-02
CL2010000788A1 (es) 2011-02-18
IL225633A0 (en) 2014-03-31
AR038970A1 (es) 2005-02-02
MXPA04008870A (es) 2005-06-17
WO2003100033A3 (en) 2004-07-15
JP2015091807A (ja) 2015-05-14
US20090186036A1 (en) 2009-07-23
JP5616932B2 (ja) 2014-10-29
HK1074381A1 (en) 2005-11-11
ES2389037T3 (es) 2012-10-22
HK1213007A1 (zh) 2016-06-24
CL2010000790A1 (es) 2011-02-18
NO334834B1 (no) 2014-06-16
JP2013014592A (ja) 2013-01-24
AU2003261071C1 (en) 2008-12-11
EP2287199A2 (en) 2011-02-23
RS52488B (sr) 2013-02-28
AU2003261071A1 (en) 2003-12-12
PL216223B1 (pl) 2014-03-31
AU2003261071B2 (en) 2008-05-15
RS80704A (sr) 2006-12-15
NO20044347L (no) 2004-12-13
CL2010000791A1 (es) 2011-02-18
KR20040095281A (ko) 2004-11-12
CL2010000792A1 (es) 2011-02-18
CA2478833A1 (en) 2003-12-04
IS7443A (is) 2004-09-09
EP1490110A2 (en) 2004-12-29
JP2005528099A (ja) 2005-09-22
MY147019A (en) 2012-10-15
CN102924598B (zh) 2014-12-31
EP1490110A4 (en) 2006-12-27
JP2009100763A (ja) 2009-05-14
US20050255102A1 (en) 2005-11-17
JP2012228269A (ja) 2012-11-22
CN102924598A (zh) 2013-02-13
EP2287199A3 (en) 2011-05-25
CN1646160A (zh) 2005-07-27
CN102659946A (zh) 2012-09-12
BRPI0308585B8 (pt) 2021-05-25
PL372662A1 (en) 2005-07-25
US20150140609A1 (en) 2015-05-21
EP1490110B1 (en) 2012-06-13
IL225633B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
ME00804B (me) Anti-alpha v beta 6 antitela
JP2005528099A5 (me)
ME02581B (me) Farmaceutski pripravci s otpornošću na topljivi cea
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
JP2022079549A5 (me)
JP2020514310A5 (me)
JP2021106617A5 (me)
RU2009101788A (ru) Направленные на опухоль моноклональные антитела против fzd10 и их применение
HRP20131085T1 (hr) Uporaba antagonistiäśkih anti-cd40 monoklonskih antitijela
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
RU2012112829A (ru) Анти-gitr-антитела
HRP20150965T1 (hr) Anti-fgr3 protutijela i metode koje ih koriste
JP2013056885A5 (me)
HRP20192347T1 (hr) Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
HRP20250474T2 (hr) Antitijela koja se vežu za egfr i cmet
RU2011108260A (ru) Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
HRP20171301T1 (hr) Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38
SI2342234T1 (en) MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
HRP20110620T1 (hr) PROTUTIJELO PROTIV EpCAM I NJEGOVE UPOTREBE
JP2010504755A5 (me)
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2009541204A5 (me)